# Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained
> Note: PeptIQ is not a medical provider. Mazdutide availability and approval status vary by country. This article explains published trial doses for education only.
Mazdutide is a once-weekly glucagon / GLP-1 dual agonist (Innovent / Lilly partnership lineage in development communications). For SEO and clinical literacy, the dose story is unusually clean compared with some pipeline drugs: Phase 3 obesity work in China centered on 4 mg and 6 mg once weekly.
Quick Answer: Mazdutide Dosage
| Setting | Dose |
|---|---|
| Phase 3 GLORY-1 maintenance arms | 4 mg or 6 mg once weekly SC |
| Comparator | Placebo |
| Duration highlighted | Weight endpoints at 32 and 48 weeks |
GLORY-1 Results Snapshot (NEJM)
In Chinese adults with BMI criteria for overweight/obesity (regional cutoffs differ from some Western trials), once-weekly mazdutide produced clinically meaningful weight loss vs placebo.
Approximate treatment-policy style means reported:
| Timepoint | 4 mg | 6 mg | Placebo |
|---|---|---|---|
| Week 32 weight change | ~−10.1% | ~−12.6% | ~+0.5% |
| Week 48 weight change | ~−11.0% | ~−14.0% | ~+0.3% |
At week 32, large majorities on active drug hit ≥5% weight loss vs a small minority on placebo. Higher-dose (6 mg) arms also drove higher rates of ≥15% loss by week 48 in the public tables.
Why 4 mg vs 6 mg Matters
Same dual-agonist logic as survodutide/retatrutide conversations:
- 4 mg — strong efficacy with potentially gentler average tolerability for some patients
- 6 mg — higher mean loss and higher deep-responder rates in Phase 3 summaries
Titration still matters even when the headline maintenance doses look simple. Public communications describe escalation to the randomized maintenance dose rather than starting at 6 mg on day one.
Mazdutide vs Survodutide vs Tirzepatide
| Drug | Pathway | Public weekly anchors |
|---|---|---|
| Mazdutide | Glucagon + GLP-1 | 4 mg / 6 mg (GLORY-1) |
| Survodutide | Glucagon + GLP-1 | up to 3.6 / 6.0 mg (SYNCHRONIZE-1) |
| Tirzepatide | GIP + GLP-1 | Approved labeled titration schedule |
Milligrams are not convertible across molecules.
Regional Evidence Caveat (Important for SEO Honesty)
GLORY-1 enrolled Chinese adults with BMI thresholds that differ from some US trial norms. Mean baseline BMI was lower than many Western obesity Phase 3 cohorts. That does not invalidate the drug — it means you should not paste percentages onto every population without reading inclusion criteria.
What to Track on a Weekly Dual Agonist
- Maintenance dose (4 vs 6 mg) and escalation dates
- GI symptom scores after injection day
- Protein + resistance training
- Waist and average weight
- Cardiometabolic labs when ordered (BP, lipids, glucose)
FAQ
Q: What is the standard mazdutide dose?
A: Phase 3 obesity arms used 4 mg and 6 mg once weekly. Local labels (where approved) govern real-world use.
Q: Is mazdutide stronger than semaglutide?
A: Cross-trial comparisons are imperfect. Use head-to-head data when available; otherwise compare estimands and populations carefully.
Q: Is mazdutide a peptide I can reconstitute from a research vial?
A: Clinical products and research-market powders are not the same. Prefer regulated channels and clinician oversight.
Q: Daily or weekly?
A: Once weekly in the Phase 3 obesity program described here.
Bottom Line
Mazdutide dosing is one of the cleaner dual-agonist stories online: weekly 4 mg and 6 mg Phase 3 anchors with double-digit mean weight loss through 48 weeks in GLORY-1. Pair that clarity with population caveats and disciplined tracking.
Download PeptIQ to log weekly dual-agonist dose steps and outcomes.
Educational content only. Not medical advice.
